Tokyo Tape
Sign in
← Trans Genic

Quarterly report · Q2

2342.TEDINET S100S7OP
Period2023-04-01 → 2023-09-30
Filed2023-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥6.4bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥11.4bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥5.5bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥89m2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥135m2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥95m2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥199m2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥204m2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥94m2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥157m2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥48m2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥410m2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥55m2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥42m2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥55m2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥10.5bnat 2023-09-30Cons.Assets
Total assets¥10.7bnat 2023-03-31Cons.Assets
Total assets¥10.7bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥4.4bnat 2023-09-30Cons.Liabilities
Total liabilities¥4.6bnat 2023-03-31Cons.Liabilities
Net assets / equity¥6.1bnat 2023-09-30Cons.Net assets
Net assets / equity¥6.1bnat 2023-03-31Cons.Net assets
Net assets / equity¥6.6bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥2.9bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥3.5bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥2.9bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥3.5bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥3.4bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥4.6bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow−¥366m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow−¥1.4bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥696m2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥129m2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥216m2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥601m2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥47m2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥485m2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥65m2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥2.872023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-1.762023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-24.322022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥3.262022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥4.792022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio57.4%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio56.4%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio60.8%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 32
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥3m
Reconciling Itemsreconcilingrevenue external2023-04-01 → 2023-09-30¥450,000
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥4m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥108m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥981m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥978m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥3m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2023-04-01 → 2023-09-30−¥27m
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue2023-04-01 → 2023-09-30¥5.4bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2023-04-01 → 2023-09-30¥5.4bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥628,000
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2023-04-01 → 2023-09-30¥223m
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥6.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥6.4bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥4m
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥196m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥2m
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-09-30¥1m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥3m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥111m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥1.3bn
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥1.3bn
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3m
jpcrp040300-q2r_E05317-000Drug Discovery Support Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥153m
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue2022-04-01 → 2022-09-30¥4.3bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue external2022-04-01 → 2022-09-30¥4.3bn
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥187,000
jpcrp040300-q2r_E05317-000Investments And Consulting Businessreportable segmentsegment profit2022-04-01 → 2022-09-30¥92m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥5.5bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥5.5bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥3m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥246m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 493
ItemContextValueUnit
Other clPrior1YearInstant338403000JPY
Other clCurrentQuarterInstant195423000JPY
Current liabilitiesPrior1YearInstant2743992000JPY
Current liabilitiesCurrentQuarterInstant2818378000JPY
Bonds payablePrior1YearInstant137000000JPY
Bonds payableCurrentQuarterInstant130000000JPY
Long term loans payablePrior1YearInstant1569482000JPY
Long term loans payableCurrentQuarterInstant1326851000JPY
Long term accounts payable otherPrior1YearInstant27562000JPY
Long term accounts payable otherCurrentQuarterInstant19494000JPY
Net defined benefit liabilityPrior1YearInstant40892000JPY
Net defined benefit liabilityCurrentQuarterInstant36998000JPY
Other nclPrior1YearInstant31482000JPY
Other nclCurrentQuarterInstant31008000JPY
Noncurrent liabilitiesPrior1YearInstant1806419000JPY
Noncurrent liabilitiesCurrentQuarterInstant1544353000JPY
LiabilitiesPrior1YearInstant4550412000JPY
LiabilitiesCurrentQuarterInstant4362732000JPY
Capital stockPrior1YearInstant50000000JPY
Capital stockCurrentQuarterInstant50000000JPY
Capital surplusPrior1YearInstant3869990000JPY
Capital surplusCurrentQuarterInstant3861314000JPY
Retained earningsPrior1YearInstant2147300000JPY
Retained earningsCurrentQuarterInstant2111476000JPY
Treasury stockPrior1YearInstant-76915000JPY
Treasury stockCurrentQuarterInstant-57331000JPY
Shareholders equityPrior1YearInstant5990375000JPY
Shareholders equityCurrentQuarterInstant5965459000JPY
Valuation difference on available for sale securitiesPrior1YearInstant9064000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant30614000JPY
Foreign currency translation adjustmentPrior1YearInstant18401000JPY
Foreign currency translation adjustmentCurrentQuarterInstant25266000JPY
Valuation and translation adjustmentsPrior1YearInstant27465000JPY
Valuation and translation adjustmentsCurrentQuarterInstant55881000JPY
Subscription rights to sharesPrior1YearInstant200000JPY
Subscription rights to sharesCurrentQuarterInstant200000JPY
Non controlling interestsPrior1YearInstant104478000JPY
Non controlling interestsCurrentQuarterInstant98205000JPY
Net assetsPrior1YearInstant6122519000JPY
Net assetsCurrentQuarterInstant6119746000JPY
Liabilities and net assetsPrior1YearInstant10672931000JPY
Liabilities and net assetsCurrentQuarterInstant10482478000JPY
Net salesPrior1YTDDuration5542343000JPY
Net salesCurrentYTDDuration6377299000JPY
Cost of salesPrior1YTDDuration4430836000JPY
Cost of salesCurrentYTDDuration5212219000JPY
Gross profitPrior1YTDDuration1111507000JPY
Gross profitCurrentYTDDuration1165079000JPY
Selling general and administrative expensesPrior1YTDDuration976732000JPY
Selling general and administrative expensesCurrentYTDDuration1076556000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass